ArticleCNS neuroscience & therapeutics2020
LncRNA FOXD1-AS1 acts as a potential oncogenic biomarker in glioma.
Article in CNS neuroscience & therapeutics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 44 citations in OpenAlex.
- Shedding light on function of long non-coding RNAs (lncRNAs) in glioblastoma.Non-coding RNA research · 2024Review
- Techniques for investigating lncRNA transcript functions in neurodevelopment.Molecular psychiatry · 2024Review
- Review
- A novel immunogenic cell death-related gene risk signature can identify biomarkers of gliomas and predict the immunotherapeutic response.American journal of cancer research · 2024Article
- LMNB1 targets FOXD1 to promote progression of prostate cancer.Experimental and therapeutic medicine · 2023Article
- Identification of MIR600HG/hsa-miR-342-3p/ANLN network as a potential prognosis biomarker associated with lmmune infiltrates in pancreatic cancer.Scientific reports · 2023Article
- LncRNA LINC01018/miR-942-5p/KNG1 axis regulates the malignant development of glioma in vitro and in vivo.CNS neuroscience & therapeutics · 2023Article
- SLC11A1 as a stratification indicator for immunotherapy or chemotherapy in patients with glioma.Frontiers in immunology · 2022Article
- GDF15 expression in glioma is associated with malignant progression, immune microenvironment, and serves as a prognostic factor.CNS neuroscience & therapeutics · 2022Article
- Evolving Insights Into the Biological Function and Clinical Significance of Long Noncoding RNA in Glioblastoma.Frontiers in cell and developmental biology · 2022Review
- Latest updates on cellular and molecular biomarkers of gliomas.Frontiers in oncology · 2022Review
- Ferroptosis-related gene signature predicts prognosis and immunotherapy in glioma.CNS neuroscience & therapeutics · 2021Article
- The role of MMolecular therapy. Nucleic acids · 2021Review
- The Role of LncRNAs in Translation.Non-coding RNA · 2021Review
- Long Noncoding RNA AATBC Promotes the Proliferation and Migration of Prostate Cancer Cell Through miR-1245b-5p/CASK Axis.Cancer management and research · 2021Article
- Roles of Long Noncoding RNAs in Conferring Glioma Progression and Treatment.Frontiers in oncology · 2021Review
- FOXD1-AS1 regulates FOXD1 translation and promotes gastric cancer progression and chemoresistance by activating the PI3K/AKT/mTOR pathway.Molecular oncology · 2021Article
- LncRNA NFIA-AS2 promotes glioma progression through modulating the miR-655-3p/ZFX axis.Human cell · 2020Article
- Eukaryotic translation initiation factor 5A in the pathogenesis of cancers.Oncology letters · 2020Review
- LncRNA CCAT2 promotes angiogenesis in glioma through activation of VEGFA signalling by sponging miR-424.Molecular and cellular biochemistry · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsAltered activities of long noncoding RNAs (lncRNAs) have been associated with cancer development, and lncRNA FOXD1-AS1 (FOXD1-AS1) is the antisense transcript of the gene encoding for FOXD1, known for its role as an oncogene in several tumor types including glioma. However, the role of FOXD1-AS1 in the differentiation and progression of glioma is not well known.
methodsExpression profile chip and qPCR were used to screen and identify FOXD1-AS1. Glioma cells were transfected with siRNA or eukaryotic expression vector to observe FOXD1-AS1 function in vitro and in vivo. Dual luciferase reporter gene analysis, Western blot, and ChIRP-MS were used to detect microRNAs and protein that combine with FOXD1-AS1.
resultsFOXD1-AS1 was upregulated and directly correlated with the glioma grade, and it was localized in both the nucleus and the cytoplasm of the glioma cell. FOXD1-AS1 silencing caused tumor suppressive effects via inhibiting cell proliferation, migration, and apoptosis, while FOXD1-AS1 overexpression resulted in opposite effects. Additionally, in vivo experiments showed that FOXD1-AS1 knockdown reduced tumor volume and weight. More importantly, mechanical studies revealed that FOXD1-AS1 targeted both miR339-5p and miR342-3p (miR339/342). Furthermore, protein eukaryotic translation initiation factor 5 subunit A (eIF5a) resulted a direct target of FOXD1-AS1.
conclusionsThese data indicated that FOXD1-AS1, a miR339/342 target, affected biological processes via protein eIF5a; thus, it might be considered as a new therapeutic target for glioblastoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.